PD-L1 Expressing Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer lacking expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Among TNBCs, those expressing Programmed Death-Ligand 1 (PD-L1) represent a distinct immunogenic subset with unique diagnostic and therapeutic implications. Immunogenicity of PD-L1 Expressing TNBC Understanding PD-L1